基线雌二醇血清浓度对高危绝经后女性阿那曲唑预防乳腺癌疗效的影响:IBIS-II预防试验的病例对照研究
该病例对照研究基于IBIS-II预防试验,分析基线雌二醇-性激素结合球蛋白比值对阿那曲唑预防乳腺癌疗效的影响。结果显示,安慰剂组乳腺癌风险随雌二醇-性激素结合球蛋白比值每升高一个四分位数而增加(趋势比1.25,95%CI 1.08-1.45,p=0.0033),而阿那曲唑组无此趋势(1.06,0.86-1.30,p=0.60)。阿那曲唑的相对获益见于雌二醇-性激素结合球蛋白比值的第2、3、4四分位组,第1四分位组未见获益。
要点
- 安慰剂组乳腺癌风险随雌二醇-性激素结合球蛋白比值每升高一个四分位数而增加(趋势比1.25,p=0.0033)。
- 阿那曲唑组未观察到雌二醇-性激素结合球蛋白比值与乳腺癌风险的显著趋势(趋势比1.06,p=0.60)。
- 阿那曲唑的相对获益见于雌二醇-性激素结合球蛋白比值的第2、3、4四分位组,第1四分位组未显示获益。
核心结论
- 结果提示血清激素应更常规检测并纳入风险管理决策。
- 检测血清激素浓度费用低廉,可能帮助临床医生区分哪些女性将从芳香化酶抑制剂中获益最大。
研究设计与样本
- IBIS-II预防试验是一项在18个国家153个乳腺癌治疗中心开展的随机、对照、双盲试验,纳入40-70岁高危绝经后女性。
- 试验中女性按1:1随机接受阿那曲唑(1 mg/日,口服)或安慰剂每日治疗5年。
- 本预先计划的病例对照研究主要分析基线雌二醇-性激素结合球蛋白比值对全部乳腺癌(包括导管原位癌)发生的影响。
- 病例为 trial entry 后至2019年10月22日 cutoff 期间报告乳腺癌、有有效血样且 trial entry 前3个月内或试验期间未使用激素替代治疗的参与者。
- 每例病例随机选取2例无乳腺癌对照,按治疗组、年龄(相差2岁以内)和随访时间(至少与匹配病例相同)匹配。
主要发现
- 试验于2003年2月2日至2012年1月31日招募3864名女性,随机分配至阿那曲唑组(n=1920)或安慰剂组(n=1944)。
- 中位随访131个月(IQR 106-156),阿那曲唑组发现85例(4.4%)乳腺癌,安慰剂组165例(8.5%)。
- 排除后,病例对照研究纳入阿那曲唑组212名参与者(72例病例,140例对照)和安慰剂组416名(142例病例,274例对照)。
- 安慰剂组乳腺癌风险随雌二醇-性激素结合球蛋白比值每升高一个四分位数而增加(趋势比1.25,95%CI 1.08-1.45,p=0.0033),阿那曲唑组无此趋势(1.06,0.86-1.30,p=0.60)。
- 安慰剂组睾酮-性激素结合球蛋白比值趋势比较弱(趋势比1.21,95%CI 1.05-1.41,p=0.011),阿那曲唑组无显著趋势(1.18,0.96-1.46,p=0.11)。
临床怎么用
- 作者认为血清激素应更常规检测并纳入风险管理决策。
- 作者认为检测血清激素浓度费用低廉,可能帮助临床医生区分哪些女性将从芳香化酶抑制剂中获益最大。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increased risk of breast cancer is associated with high serum concentrations of oestradiol and testosterone in postmenopausal women, but little is known about how these hormones affect response to endocrine therapy for breast cancer prevention or treatment. We aimed to assess the effects of serum oestradiol and testosterone concentrations on the efficacy of the aromatase inhibitor anastrozole for the prevention of breast cancer in postmenopausal women at high risk. METHODS: In this case-control study we used data from the IBIS-II prevention trial, a randomised, controlled, double-blind trial in postmenopausal women aged 40-70 years at high risk of breast cancer, conducted in 153 breast cancer treatment centres across 18 countries. In the trial, women were randomly assigned (1:1) to receive anastrozole (1 mg/day, orally) or placebo daily for 5 years. In this pre-planned case-control study, the primary analysis was the effect of the baseline oestradiol to sex hormone binding globulin (SHBG) ratio (oestradiol-SHBG ratio) on the development of all breast cancers, including ductal carcinoma in situ (the primary endpoint in the trial). Cases were participants in whom breast cancer was reported after trial entry and until the cutoff on Oct 22, 2019, and who had valid blood samples and no use of hormone replacement therapy within 3 months of trial entry or during the trial. For each case, two controls without breast cancer were selected at random, matched on treatment group, age (within 2 years), and follow-up time (at least that of the matching case). For each treatment group, we applied a multinominal logistic regression likelihood-ratio trend test to assess what change in the proportion of cases was associated with a one-quartile change in hormone ratio. Controls were used only to determine quartile cutoffs. Profile likelihood 95% CIs were used to indicate the precision of estimates. A secondary analysis also investigated the effect of the baseline testosterone-SHBG ratio on breast cancer development. We also assessed relative benefit of anastrozole versus placebo (calculated as 1 - the ratio of breast cancer cases in the anastrozole group to cases in the placebo group). The trial was registered with ISRCTN (number ISRCTN31488319) and completed recruitment on Jan 31, 2012, but long-term follow-up is ongoing. FINDINGS: 3864 women were recruited into the trial between Feb 2, 2003, and Jan 31, 2012, and randomly assigned to receive anastrozole (n=1920) or placebo (n=1944). Median follow-up time was 131 months (IQR 106-156), during which 85 (4·4%) cases of breast cancer in the anastrozole group and 165 (8·5%) in the placebo group were identified. No data on gender, race, or ethnicity were collected. After exclusions, the case-control study included 212 participants from the anastrozole group (72 cases, 140 controls) and 416 from the placebo group (142 cases, 274 controls). A trend of increasing breast cancer risk with increasing oestradiol-SHBG ratio was found in the placebo group (trend per quartile 1·25 [95% CI 1·08 to 1·45], p=0·0033), but not in the anastrozole group (1·06 [0·86 to 1·30], p=0·60). A weaker effect was seen for the testosterone-SHBG ratio in the placebo group (trend 1·21 [1·05 to 1·41], p=0·011), but again not in the anastrozole group (trend 1·18 [0·96 to 1·46], p=0·11). A relative benefit of anastrozole was seen in quartile 2 (0·55 [95% CI 0·13 to 0·78]), quartile 3 (0·54 [0·22 to 0·74], and quartile 4 (0·56 [0·23 to 0·76]) of oestradiol-SHBG ratio, but not in quartile 1 (0·18 [-0·60 to 0·59]). INTERPRETATION: These results suggest that serum hormones should be measured more routinely and integrated into risk management decisions. Measuring serum hormone concentrations is inexpensive and might help clinicians differentiate which women will benefit most from an aromatase inhibitor. FUNDING: Cancer Research UK, National Health and Medical Research Council (Australia), Breast Cancer Research Foundation, and DaCosta Fund.
引用
- Cuzick J, Chu K, Keevil B, et al. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial. Lancet Oncol. 2023. PMID: 38070530. doi:10.1016/S1470-2045(23)00578-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。